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Background: Although neoadjuvant chemoradiotherapy (CRT) has become a standard procedure to downstage
locally advanced rectal cancer prior to surgery, markers to predict the response to CRT have not been fully
identified. The aim of this study was to identify predictive factors of response to CRT, especially focusing on
peripheral blood leukocyte subsets.
Methods: A total of 45 consecutive patients diagnosed with primary rectal cancer were prospectively enrolled and
received CRT followed by curative resection. The numbers of each lymphocyte subset in peripheral blood pre- and
post-CRT were analyzed using flow cytometry. According to the pathological response to CRT, patients were
classified into high (Hi-R) and low (Lo-R) response groups.
Results: Hi-R cases had significantly higher numbers of pre-CRT lymphocytes (p = 0.018), T lymphocytes (p = 0.009)
and helper T lymphocytes (Th lymphocytes, p = 0.015) compared to the Lo-R cases. With the receiver-operating
characteristic curve for numbers of pre-CRT T lymphocytes, the area under the curve (AUC) was 0.733, and the optimal
cutoff value was 1196/μl, with 76.5% sensitivity, 67.8% specificity, 59.1% positive and 82.6% negative predictive values.
The numbers of pre-CRT Th lymphocytes and cytotoxic lymphocytes were both independent predictors of the high
CRT response in the multivariate analysis.
Conclusions: In addition to the direct cytotoxicity of CRT, recent studies have demonstrated the induction of an
immunological host response, which also contributed to the tumor regression induced by CRT. Our result suggested
the potential role of circulating T lymphocytes in predicting the response to CRT in colorectal cancer patients.
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In the recent years, combined chemoradiotherapy (CRT)
followed by total mesorectal excision has become the
standard treatment for patients with locally advanced
rectal cancer. Tumor downstaging with preoperative
CRT increases the curative resection rate and lowers the
local recurrence rate [1-3]. However, it is now evident
that the preoperative CRT is not equally effective for all
rectal cancer patients. Whereas some patients show an
important regression with no detectable cancer cells in* Correspondence: kz-kawai@mvd.biglobe.ne.jp
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unless otherwise stated.the primary tumor location or in lymph nodes in the
surgical specimens, others have only a minimal response
to CRT [4-6].
Although clinical factors such as gender, age or clinical
TNM stage had little association with CRT response [7],
many molecular predictors of tumor response to CRT
have been determined, such as p53 [8], epithelial growth
factor receptor (EGFR) [9,10], Ki-67 [11] and p21 [9].
We have also reported Ku70, Ku86, P16 and telomerase
reverse transcriptase as promising biomarkers in predict-
ing the radiosensitivity of rectal cancer [7,12,13]. Fur-
thermore, we recently reported that the gene expression
profiles of rectal cancer determined by DNA microarray
analysis were correlated with the histological regressionhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Definitions of lymphocyte subpopulations
Surface markers Subpopulation
CD3 (+)/CD19 (-) T lymphocytes
CD3 (-)/CD19 (+) B lymphocytes
CD3 (+)/CD4 (+) Helper T lymphocytes (Th lymphocytes)
CD3 (+)/CD8 (+) Cytotoxic T lymphocytes (Tc lymphocytes)
CD3 (-)/CD56 (+) Natural killer cells
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chemoradiosensitivity of rectal cancer is closely associ-
ated with the direct cytotoxic effect of radiation by indu-
cing DNA damage or apoptosis of cancer cells. However,
growing evidence indicates the possibility that the tumor
shrinkage of rectal cancer depends not only on the
radiocytotoxity to cancer cells, but also on the tumor
microenvironment and host immune response [15,16].
Recently we reported that both the density of tumor-
infiltrating lymphocytes and those circulating in periph-
eral blood strongly correlate with the response rate of
CRT in retrospective studies [17-19] and demonstrated
the involvement of antitumor immunity in the cancer
regression process induced by CRT.
In the present prospective study with new series of pa-
tients, we aimed to elucidate which subset of circulating
lymphocytes most reflects the immune response evoked
during CRT in patients with rectal cancer and analyze
their predictive ability for the response to CRT.
Methods
Patients
A total of 45 consecutive patients diagnosed with pri-
mary rectal cancer of clinical T3-4 and M0 stage at the
Department of Surgical Oncology, the University of
Tokyo Hospital between January 2010 and June 2012
were prospectively enrolled in the study. The study
protocol was approved by the local ethics committee
(Research ethics committee, Graduate school of medi-
cine and Faculty of medicine, The University of Tokyo),
and written informed consent was obtained from all pa-
tients. All patients enrolled in the study received a total
dose of 50.4 Gy of radiation and concomitant 5-FU
based chemotherapy, and they underwent standardized
curative resection, following an interval of 6–8 weeks
after CRT. Barium enema (BE) was performed before
and after CRT, and the longitudinal dimension of the
rectal tumor was measured on BE images before (A) and
after (B) CRT. The reduction rate was calculated as
(A-B)/A, as described by Suzuki et al. [20,21].
Pathological study
All of the resected specimens were examined pathologic-
ally, and the findings were recorded in accordance with
the TMN classification. The histological regression of
the primary rectal lesion in response to CRT was evalu-
ated and classified as high or low, based on the amount
of residual cancer according to the Japanese Classifica-
tion of Colorectal Carcinoma, i.e., cases in which more
than two-thirds of the cancer had degraded, necrotized
or disappeared were classified as cases of high histological
regression (Hi-R), and those with less than two-thirds
reduction were classified as low histological regression
(Lo-R).Blood sampling and analysis of leukocyte phenotypes
Peripheral venous blood samples were obtained before
neoadjuvant CRT and 4–6 weeks after completion of
CRT, prior to surgery. Samples were collected in ethyl-
ene diamine tetra-acetic acid collection tubes, and the
blood cell counts in the samples were analyzed using an
automated hematology analyzer (XE-5000, Sysmex,
Japan). Lymphocyte subsets were also analyzed using
flow cytometry, as described previously, with small mod-
ifications [22]. Briefly, whole blood was treated with
FACS Lysing Solution (Becton Dickinson) to lyse red
cells and fix leukocytes with 1% formaldehyde. Then,
leukocytes were incubated with 10 μl of each antibody
for 20 min at room temperature and analyzed in the
flow cytometer. The region of lymphocytes was gated,
and two-color flow-cytometric analysis for each cell
phenotype on 10,000 events was performed on the
FACSCalibur flow cytometer (Becton Dickinson) using
the Multiset software package (Becton Dickinson), and
the data were analyzed using the CellQuest software. A
combination of isothiocyanate (FITC) and phycoerythrin
(PE)-conjugated monoclonal antibody (Becton Dickin-
son, San Jose, CA, USA) was used to identify lymphocyte
subsets, as follows: CD3(+)/CD19(−) for the T lympho-
cytes, CD3(−)/CD19(+) for the B lymphocytes, CD3
(+)/CD4(+) for the helper T lymphocytes (Th lympho-
cytes), CD3(+)/CD8(+) for the cytotoxic T lymphocytes
(Tc lymphocytes) and CD3(−)/CD56(+) for the natural
killer cells (Table 1).Statistical analysis
The analysis of the associations between blood cell
counts or numbers of lymphocyte subsets and clinico-
pathological variables was carried out using the Mann-
Whitney U test. Association between the numbers of
lymphocytes and tumor regression rate evaluated by bar-
ium enema was analyzed using the coefficient of correl-
ation. Multivariate analysis with a logistic regression
model was used in analyzing the independency of the
predictors for CRT response. All analyses were per-
formed with JMP 9 software, and p-values < 0.05 were
considered to be statistically significant.
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Patients’ characteristics are summarized in Table 2. The
45 patients were divided into two groups according to
the pathological response, i.e., Lo-R (28 cases, 62.2%)
and Hi-R (17 cases, 37.8%), and the 8 cases of patho-
logical CR were included in the Hi-R group. The cor-
relation between the pre- or post-CRT number of
leukocyte subpopulations and the pathological response
is presented in Table 3. Cases of Hi-R had significantly
higher numbers of pre-CRT lymphocytes compared to
the Lo-R, whereas in the analysis of post-CRT peripheral
blood leukocytes, any subpopulation of leukocytes corre-
lated with the pathological response. Therefore, we fo-
cused on the pre-CRT lymphocyte subsets and analyzed
their correlation with the response to CRT. As shown in
Figure 1A, the number of T lymphocytes and Th lym-
phocytes in Hi-R group was markedly higher than that
in the Lo-R group (p = 0.009 and p = 0.015, respectively).
Although without statistical significance (p = 0.056), the
number of Tc lymphocytes also showed the same ten-
dency. As expected from the results of the blood cell
count, no difference between the Lo-R and Hi-R groupsTable 2 Patient characteristics (n = 45)
Characteristics Number of
patients (%)
Gender Male 29 (64.4)
Female 16 (35.6)
Age (years) Median 64






Low regression (Lo-R) 28 (62.2)
High regression (Hi-R) 17 (37.8)






Lymphatic invasion Absent 38 (84.4)
Present 7 (15.6)










Mucinous carcinoma 1 (2.2)
No cancer remaining 8 (17.8)
Values are number (percentage) unless otherwise noted.
*Data are expressed as mean ± SD.was observed for any lymphocyte subsets post-CRT
(Figure 1B). Similar results were obtained in the analysis
of the correlation between the number of lymphocytes
and tumor reduction rate evaluated by BE (Figure 2).
The pre-CRT total number of T lymphocytes (Figure 2A)
and Th lymphocytes (Figure 2B) significantly correlated
with the tumor reduction rate (p = 0.049 and p = 0.042,
respectively), whereas the pre-CRT number of Tc
lymphocytes (Figure 2C) and post-CRT lymphocyte sub-
sets (data not shown) showed no correlation. The higher
the number of pre-CRT lymphocytes, the higher the
tumor regression achieved was. Figure 3 represents the
receiver-operating characteristic (ROC) curve for numbers
of pre-CRT T lymphocytes, Th and Tc lymphocytes in
predicting the pathological response in the Hi-Response
group. The area under the curve (AUC) was 0.733, 0.718
and 0.671, respectively. The optimal cutoff value of T lym-
phocytes was 1,196/μl, with 76.5% sensitivity, 67.8% speci-
ficity, 59.1% positive predictive value (PPV) and 82.6%
negative predictive value (NPV). The cutoff value of Th
lymphocytes was 683/μl, with 71.4% sensitivity, 76.5% spe-
cificity, 61.9% PPV and 83.3% NPV. The cutoff value of Tc
lymphocytes was 367/μl, with 53.6% sensitivity, 88.2% spe-
cificity, 53.6% PPV and 88.2% NPV. Based on these cutoff
values, each lymphocyte subset was divided into two
groups, namely lower and higher, and multivariate analysis
of each factor in predicting CRT response was performed.
As shown in Table 4, none of the pre-CRT clinical factors
showed a correlation with the CRT response, whereas
high pre-CRT Th and Tc lymphocytes were independent
predictive factors of a good response to therapy.
We evaluated the association between lymphocyte
subsets and the clinicopathological variables of the
resected specimens. However, as presented in Table 5,
both pre- and post-CRT lymphocyte subsets showed al-
most no correlation with the clinicopathological factors.
Although the post-CRT number of B lymphocytes was
higher in males than females (p = 0.026), and the num-
ber of natural killer cells in both pre- and post-CRT was
higher in the cases with venous invasion (p = 0.024 and
p = 0.018, respectively), these subsets account for only a
small proportion of lymphocytes; thus, the clinical im-
pact of these findings remains to be elucidated. The re-
ductions in the number of T lymphocytes, Th and Tc
lymphocytes during CRT are also shown in Figure 4. A
significantly higher reduction in the number of T, Th
and Tc lymphocytes during CRT was observed in the T0-2
than in the T3/4 group (p = 0.022, p = 0.034 and p = 0.026,
respectively).
Discussion
In recent years, CRT has become one of the standard
therapeutic modalities for the treatment of rectal cancer.
Although CRT for rectal cancer has been shown to
Table 3 The relations between the pathological response and subpopulations of leukocytes, pre- and post- CRT
Pre-CRT Post-CRT
Lo-R Hi-R P value Lo-R Hi-R P value
White blood cells (cells/μl) 6,250 (2,800 − 9,400) 6,500 (3,700 − 9,600) 0.150 White blood cells (cells/μl) 4,700 (2,300 − 7,300) 4,300 (2,200 − 9,100) 0.598
Neutrophils (%) 65.9 (53.2 − 79) 60.2 (45.2 − 72.9) 0.106 Neutrophils (%) 71.1 (51 − 85.5) 70.1 (53 − 79.8) 0.543
Neutrophils (cells/μl) 4,211 (1,652 − 6,476) 4,250 (1,898 − 6,257) 0.743 Neutrophils (cells/μl) 3,334 (1,403 − 6,071) 2,994 (1,540– 6,379) 0.440
Lymphocytes (%) 25.9 (16.1 − 38.2) 31.5 (15.2 − 42.4) 0.261 Lymphocytes (%) 18.5 (5.5 − 33) 17 (10.9 − 36) 0.935
Lymphocytes (cells/μl) 1,510 (896 − 3,487) 1,998 (1,183 − 3,331) 0.018 Lymphocytes (cells/μl) 801 (391 − 1,351) 663 (386 − 2366) 0.743
Monocytes (%) 5.1 (3 − 10.7) 5.5 (3.8 − 9) 0.535 Monocytes (%) 6.9 (3 − 11) 7.1 (3.4 − 13) 0.752
Monocytes (cells/μl) 289 (168 − 696) 374 (185 − 801) 0.198 Monocytes (cells/μl) 278 (171 − 748) 309 (132 − 663) 0.717
Eosinophils (%) 1.5 (0 − 5.1) 3 (0.5 − 7.6) 0.040 Eosinophils (%) 2.0 (0 − 8.9) 2.9 (0.3 − 10) 0.079
Eosinophils (cells/μl) 86 (0 − 418) 177 (31 − 669) 0.010 Eosinophils (cells/μl) 84.2 (0 − 543) 112 (27.3 − 450) 0.147
Basophils (%) 0.2 (0 − 1.3) 0.4 (0 − 1.3) 0.277 Basophils (%) 0.3 (0 − 2) 0.2 (0 − 1) 0.307













Figure 1 The correlation between the pathological response and number of peripheral blood lymphocyte subsets before CRT. Filled
bars represent numbers of cells of pre-CRT (A) and post-CRT (B) in the Lo-R group and blank bars in the Hi-R group. Data are expressed as mean
+ SD of results. *Statistical significance.
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that preoperative CRT is not equally effective for all rec-
tal cancer patients. If tumor response could be predicted
before surgery, CRT-related toxicity and expense could
be avoided for patients with resistant tumors, and/or
more aggressive preoperative regimens could be consid-
ered for those patients. Therefore, a number of trials
have been conducted to identify a useful marker for the
prediction of the response to CRT [7-14]. Although
most of the biomarkers identified so far are factors re-
lated to the radio-resistance of cancer cells themselves,
in recent years, it has been elucidated that the immuno-
logical host response is also essential for tumor regres-
sion in CRT. Experimental T cell elimination remarkably
reduced the therapeutic efficacy of radiation in a mouse
model [23], and we have previously demonstrated that
the densities of CD4(+) and CD8(+) tumor-infiltratinglymphocytes (TIL) were significantly associated with the
histological grade after CRT, and the density of CD8(+)
TIL was an independent prognostic factor for achieving
CR after CRT [19]. Recently, we reported that a high
pre-CRT lymphocyte count in the peripheral blood of
rectal cancer patients was significantly associated with
pathological response [18]. A similar result was also re-
ported from Korea [24], but the subset of circulating
lymphocytes mostly involved in the antitumor immunity
evoked during CRT remains to be elucidated. Therefore,
in this prospective study, we aimed to clarify whether
circulating lymphocytes could reflect local immuno-
logical response and, if so, to identify the subset of lym-
phocytes mostly involved, which might be used as a
potential predictor of the pathological CRT response.
Initially, we evaluated the association between peri-
pheral blood leukocyte counts and the pathological
Figure 2 The numbers of lymphocyte subsets before CRT and tumor reduction ratio in response to CRT. The longitudinal length of the
rectal tumor was measured by barium enema before and after CRT, and the tumor reduction ratio was calculated. Histological response grade
was evaluated by the pathologists, according to the definitions in the Japanese Classification of Colorectal Carcinoma. The correlations between
the numbers of T lymphocytes (A), Th lymphocytes (B) and Tc lymphocytes (C) and tumor reduction rate are presented. Correlations of
coefficient are presented as r.
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Figure 3 The receiver-operating characteristic (ROC) curve for the numbers of pre-CRT T lymphocytes (A), Th lymphocytes (B) and Tc
lymphocytes (C) in predicting the pathological high response group. The X-axis represents “1–sensitivity” and the Y-axis, the sensitivity. The
areas under the curve for each ROC curve are shown.
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cantly higher pre-CRT number of circulating lympho-
cytes than those with low response, corroborating the
results of previous reports [18,24]. Because the lympho-
cyte population assessed by the hematology analyzer
contains several subsets, further analysis of lymphocyte
subsets using flow cytometry was conducted. Pre-CRT
circulating T lymphocytes and Th lymphocytes, but not
B lymphocytes, showed a significant correlation with the
pathological response and the tumor regression rate, and
a high T lymphocyte or Th lymphocyte count correlated
with a larger tumor reduction. Both T and B lympho-
cytes significantly decreased during CRT, and the post-
CRT lymphocyte subsets did not differ between the
high- and low-response groups. A number of precedent
studies have documented the participation of T lympho-
cytes, but not B lymphocytes, in the radiation-induced
antitumor immunity [16,25], and our present results
were also concordant. The AUC of pre-CRT T lympho-
cytes in predicting the low-response group was as high
as 0.733, and in multivariate analysis, the numbers of Th
lymphocytes and Tc lymphocytes were independent pre-
dictors of response to CRT. Because the negative pre-
dictive values of each lymphocyte subset in predicting
good response were higher than 80%, lymphocytes sub-
sets should be a promising marker for the screening ofTable 4 Multivariate analysis of clinical factors in predicting C
Univaria
P value
Gender Male vs. female 0.9758
Age ≦65 vs. >65 0.6547
Clinical T T3 vs. T4 0.8847
Clinical N N0 vs. N+ 0.6547
T lymphocytes ≦1,196 vs. >1,196 (cells/μl) 0.0033
Th lymphocytes ≦683 vs. >683 (cells/μl) 0.0015
Tc lymphocytes ≦367 vs. >367 (cells/μl) 0.0032CRT-resistant patients prior to CRT, thus avoiding un-
necessary CRT. Some of the previously reported predict-
ive factors of the CRT effect were based on the analysis
of the surgically resected specimens; thus, their value as
a predictive marker of CRT is low. For their analysis, bi-
opsy specimens are necessary, which hold two problems:
first, the findings obtained from post-CRT resected spec-
imens may be affected by the CRT, not reflecting the pri-
mary nature of the tumor; second, the biopsy samples
do not necessarily represent the whole cancer tissue
because of the heterogeneity of cancer. In this respect,
peripheral blood lymphocytes, which are easily ob-
tained through the collection of a small amount of
blood and represent the systemic immunologic condi-
tion, might have an advantage over these previously re-
ported markers.
The correlation between lymphocytes in peripheral
blood and tumor-infiltrating lymphocytes (TIL) has not
been fully investigated. Milne et al. have reported that
the lymphocyte count in peripheral blood did not correl-
ate with CD8 (+) or CD20 (+) TIL in patients with ovar-
ian cancer, and both lymphocyte count and TIL
significantly correlated with prognosis, but the correla-
tions were independent of each other [26]. Therefore,
the role of circulating lymphocytes in antitumor immun-
ity remains to be clarified; however, a number of reportsRT response
te Multivariate
Hazard ratio 95% CI P value
1.46 0.18 − 14.6 0.7261
10.56 1.5 − 99.6 0.0124
11.38 1.5 − 146.4 0.0194
Table 5 The correlations between the clinicopathological factors and numbers of lymphocyte subsets, pre- and
post- CRT
Gender Pre-CRT Post-CRT
Male Female P value Male Female P value
T lymphocytes 1,196 (675 − 2,273) 1,046 (686 − 1,688) 0.325 608 (258 − 1,240) 455 (321 − 1,856) 0.228
Th lymphocytes 667 (329 − 1,489) 587 (383 − 1,180) 0.619 248 (89 − 696) 196 (118 − 692) 0.334
Tc lymphocytes 448 (258 − 855) 374 (200 − 847) 0.083 324 (119 − 671) 238 (137 − 1,144) 0.441
B lymphocytes 140 (31 − 675) 173 (30 − 409) 0.822 40 (1 − 185) 20 (9 − 73) 0.026
Natural killer cells 259 (56 − 966) 236 (135 − 1,020) 0.831 179 (15 − 811) 162 (35 − 497) 0.519
Depth of invasion Pre-CRT Post-CRT
pT0-2 pT3/4 P value pT0-2 pT3/4 P value
T lymphocytes 1,196 (732 − 2,217) 1,157 (675 − 2,273) 0.489 482 (258 − 1,010) 694 (268 − 1,856) 0.136
Th lymphocytes 683 (329 − 1,496) 513 (361 − 1,364) 0.525 215 (89 − 620) 276 (99 − 696) 0.120
Tc lymphocytes 458 (200 − 847) 394 (270 − 855) 0.658 268 (141 − 495) 348 (119 − 1,144) 0.182
B lymphocytes 172 (73 − 675) 143 (30 − 459) 0.594 31 (1 − 140) 24 (9 − 185) 0.619
Natural killer cells 221 (135 − 966) 268 (56 − 1,020) 0.586 167 (28 − 335) 179 (15 − 811) 0.261
Lymph node metastasis Pre-CRT Post-CRT
Absent Present P value Absent Present P value
T lymphocytes 1,135 (675 − 2,273) 1,233 (686 − 1,399) 0.507 494 (268 − 1,856) 628 (258 − 1,240) 0.332
Th lymphocytes 665 (329 − 1,496) 641 (383 − 907) 0.395 217 (99 − 696) 276 (89 − 564) 0.346
Tc lymphocytes 430 (258 − 855) 439 (200 − 752) 0.970 307 (119 − 1144) 316 (167 − 671) 0.324
B lymphocytes 178 (77 − 675) 122 (30 − 459) 0.089 26.5 (9 − 185) 30 (1 − 94) 0.769
Natural killer cells 260 (56 − 929) 232 (124 − 1,020) 0.590 173.5 (15 − 811) 174 (45 − 552) 0.837
Lymphatic invasion Pre-CRT Post-CRT
Absent Present P value Absent Present P value
T lymphocytes 1,181 (732 − 2,273) 895 (675 − 2,217) 0.247 494 (258 − 1,856) 694 (366 − 1,240) 0.136
Th lymphocytes 675 (329 − 1,364) 602 (361 − 1,496) 0.491 210 (89 − 696) 276 (226 − 564) 0.100
Tc lymphocytes 453 (258 − 855) 350 (200 − 694) 0.434 268 (137 − 1,144) 348 (119 − 671) 0.206
B lymphocytes 167 (30 − 675) 122 (33 − 185) 0.103 27 (1 − 185) 30 (10 − 70) 0.931
Natural killer cells 232 (56 − 1,020) 495 (135 − 929) 0.199 167 (28 − 811) 201 (15 − 552) 0.283
Venous invasion Pre-CRT Post-CRT
Absent Present P value Absent Present P value
T lymphocytes 1,122 (675 − 2,273) 1,181 (686 − 2,217) 0.774 481 (328 − 1,200) 619 (258 − 1,856) 0.227
Th lymphocytes 722 (329 − 1,364) 607 (383 − 1,496) 0.505 224 (146 − 696) 265 (89 − 692) 0.896
Tc lymphocytes 371 (200 − 855) 464 (258 − 847) 0.228 233 (119 − 495) 321 (137 − 1,144) 0.112
B lymphocytes 193 (73 − 409) 137 (30 − 675) 0.370 29 (10 − 185) 25 (1 − 121) 0.520
Natural killer cells 210 (117 − 498) 314 (56 − 1,020) 0.024 132 (15 − 811) 201 (80 − 552) 0.018
Data are expressed as median (range).
Pre-CRT: measured before chemoradiation therapy; post-CRT: measured after chemoradiation therapy.
Tada et al. World Journal of Surgical Oncology  (2015) 13:30 Page 8 of 10have documented the association of a high peripheral
lymphocyte count and favorable prognosis in patients
with various types of malignancies including uterine, cer-
vix, breast and nasopharyngeal carcinoma [27,28]. Our
prospective study advanced these precedent findings in
raising the following issues. First, peripheral lymphocytes
seem to play a crucial role not only in treatment-naïve
cancer tissue, but also in the CRT-mediated systemic an-
ticancer immunological response. Second, among thevarious lymphocyte subsets, T lymphocytes, especially
Th lymphocytes, seem to play a central role in the im-
munological response.
We also evaluated the association between the clinico-
pathological factors and the pre- and post-CRT periph-
eral lymphocyte subset counts. Contrary to the analysis
of pathological regression, neither pre- nor post-CRT
lymphocyte subsets showed a correlation with the
clinicopathological factors. Interestingly, in cases with
Figure 4 The correlations between the reductions in numbers
of lymphocyte subsets during CRT and pathological T factor of
the resected specimens. Shaded bars represent the reduction in
numbers of each lymphocyte subset in the T0-2 cases and blank
bars in the T3/4 cases. Data are expressed as mean ± SD of results.
*Statistical significance.
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the higher reduction of T lymphocytes and Tc lympho-
cytes was induced by CRT. We previously reported that
in vitro radiation-induced apoptosis of peripheral blood
lymphocytes is correlated with histological regression of
preoperative CRT [29], and the present finding of the
correlation between the clinical reduction of lymphocytes
induced by CRT and the downstaging of T factor strongly
supports our previous finding.
Several problems, however, still remain to be addressed
in our present study. Pathological regression strongly cor-
related with pre-CRT Th, but not Tc lymphocyte counts.
In contrast, downstaging of the T factor correlated with
post-CRT, but not with pre-CRT, Tc or Th lymphocyte
counts. Cancer cells undergo apoptosis by the direct cyto-
toxic effect of radiation or chemotherapy, and conse-
quently release cancer-specific antigens. These released
antigens are phagocytized by antigen-presenting cells,
such as macrophages or dendritic cells, resulting in induc-
tion of tumor-specific Th and Tc lymphocyte responses
[30-32]. Furthermore, irradiated tissue releases various
chemoattractant factors, such as CCL11 or CXCL16
[33,34], and promotes infiltration of lymphocytes into
the cancer tissue. A more detailed role of peripheral Th
and Tc lymphocytes in these processes should be clari-
fied in further investigations. Another problem is that
the observation period of this study was relatively short,
and there were only a few patients with postoperative
recurrence; thus, the effect of lymphocytes on prognosis
is still unclear. Further investigation with a larger num-
ber of patients and longer follow-up period is desired.
Conclusions
Both systemic and local immunity may play important
roles in antitumor immunity, and from our present data,
the analysis of the systemic one may efficiently predictthe response to neoadjuvant CRT. The circulating T
lymphocyte and Th lymphocyte counts would be prom-
ising markers for the prediction of response to CRT.
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